


RESPIRI




Annual General Meeting

15 November 2021



RESPIRI



Welcome
to Respi's
2021 AGM

From our Chairman
Nicholas Smedley

ONLINE ATTENDEES – VOTING PROCESS



1

Visit:
[web.lumiagm.com/
379 068 834](http://web.lumiagm.com/379068834)

2

Enter Username:
SRN or HIN

3

Enter Password:
**Postcode or
Country Code**




ONLINE ATTENDEES – VOTING PROCESS




4

When the poll is open, votes will be accessible by selecting the voting icon




5

To vote simply select the option you wish to send




6

Your selected vote will change colour and the number of votes made will be displayed



ONLINE ATTENDEES – QUESTION PROCESS



RESPIRI



Formal Proceedings

Nicholas Smedley
Executive Chairman

REPORTS

Financial Report, the Directors' Report & the Auditor's Report for the year ended 30th June 2021.

Any questions?

PROXIES RECEIVED

Resolution 1 – Adoption of Remuneration Report

| Resolution number | In favour | Against | Proxy's discretion | Abstained |
|-------------------|-------------------------|----------------------|----------------------|-----------|
| 1 | 112,606,405 (96.38%) | 2,978,941 (2.55%) | 1,245,983 (1.07%) | 208,667 |

Undirected proxies given to the Chairman will be allocated “in favour” of all resolutions

PROXIES RECEIVED


Resolution 2: Re-election of Marjan Mikel as a Director

| Resolution number | In favour | Against | Proxy's discretion | Abstained |
|-------------------|-------------------------|----------------------|----------------------|-----------|
| 2 | 114,159,846 (96.95%) | 2,347,157 (1.99%) | 1,245,983 (1.06%) | 32,464 |

Undirected proxies given to the Chairman will be allocated “in favour” of all resolutions

PROXIES RECEIVED

Resolution 3: Approval of 10% Placement Capacity




| Resolution number | In favour | Against | Proxy's discretion | Abstained |
|-------------------|-------------------------|----------------------|----------------------|-----------|
| 3 | 113,242,321 (96.31%) | 3,088,443 (2.63%) | 1,245,983 (1.06%) | 208,703 |

Undirected proxies given to the Chairman will be allocated “in favour” of all resolutions

QUESTIONS

Please submit
any questions you
have on the
resolutions
via Zoom
now.

RESPIRI



THANK
YOU

Our CEO will now
present a brief update

RESPIRI



Marjan Mikel
CEO/Managing Director

RESPIRI: MedTech Respiratory company extending care beyond the clinic



OUR MISSION

.....to improve asthma management by extending care beyond the clinic

OUR VISION

...a world without the challenges of asthma



"Bought 2 weeks ago and it's a fantastic tool to manage my asthma. Wish I had it long ago. Highly recommend". (user June '21)

"Amazing product. It has changed my son's life and how he deals with asthma. Sceptic at first but now wouldn't go without! Highly recommend". (user Nov '20)



4.8



4.2



2021 Highlights and work in progress


- FDA 510(k) Approval in March
- Patient Experiential Programme (PEP) completed.
 - Outcomes trends encouraging
 - Patient engagement required intervention
- Specialist lead Remote Patient Monitoring Programme (R.A.M.P.) developed as a result.
 - Dramatic improvement in patient engagement
 - Patient outcome trends very positive.
 - Model for use globally and locally as a new wheezo channel
 - Data available in Q1 2022
- Pharmacy sales have not met company expectations and plans have been adjusted accordingly.
- wheezo 4.0 developed and COGS target achieved in 2022.
- Wheezo App upgraded to include Asthma Control Questionnaire (ACT). World first.
- Winner of Good Design Gold Award for product design, medical and scientific
- New wearable product, Sorfe, developed for nocturnal asthma and exercise induced asthma monitoring



- International market launch is Physician led in reimbursed markets.
- USA:
 - In Discussions with 6 potential telehealth/RPM/chronic care partners
 - 2 non-binding Terms sheets secured.
 - Wheezo pre-marketing to commence to US institutions and Doctors in December
 - Clinical partnership with a major paediatrics hospital being finalised
- UK
 - Birmingham University Study
 - Major 3rd party funded asthma medical device outcomes study in children secured. Reimbursement Opportunity may result
 - Partners discussions ongoing
- EU
 - Potential Partner identified for 4 markets in the EU



An integrated ecosystem to support asthma management



Our Algorithm: PEP & clinical Findings

A potential new standard

Algorithm detects wheeze as well as experienced respiratory specialists¹

Comparison of the wheeze rate algorithm with expert analysis





Figure 4: Algorithm vs Experts wheeze rate. The x-axis is the wheeze rate calculated using the experts consensus and the y-axis is the wheeze rate calculated by the Wheezo algorithm.

| | | | |
|-------------|-----|---------------------------|------|
| Accuracy | 91% | Specificity | 93% |
| Sensitivity | 87% | Cohen's Kappa Coefficient | 0.81 |


wheezo[®] real world study²

Wheeze rates $\geq 3\%$ significantly correlated with more symptoms



Remote Asthma Management Programme (RAMP)

Significant improvement in patient engagement



- We have significantly improved daily interactions with the app over 2 months with improved onboarding and proactive engagement
- Learnings documented and being applied to app notifications in our updated app
- RAMP success will form a key cog and add to our real-world evidence base and further support our local and international commercialization efforts.

“A wonderful thing, allows me to understand my triggers and symptoms on the app. Have discovered a lot more triggers since using the app”

“Even though I have had asthma a long time, using the app has helped me learn to calm my breathing down, it’s made me realise how often I am taking my medication as well”

“Very easy to use, just like the whole thing, the rainbow was easy and made me feel my breathing was getting calmer”



The United States Opportunity



1 in 13¹
living with asthma

1.6 million³
ED visits with asthma

\$8,238⁴
cost per in-patient
medical event

1 in 20²
living with COPD

873k²
ED visits with COPD

\$27,597⁴
cost per in-patient
medical event

TAKEOUT: Respiratory disease places a significant burden on the US healthcare system



Respiratory illness continues to be poorly managed due to many compounding factors

In-clinic spirometry is almost impossible for all patients, let alone in the community setting¹

RPM/RTM solutions allow physicians and health networks to reduce inequity in access whilst delivering ongoing medical care for their patients⁴

Health literacy amongst patients and carers continues to contribute to poor outcomes²

Low socio-economic status increases burden of respiratory disease, especially in males⁵

Adherence to medications have historically been very poor with many studies showing adherence levels of <50%³

Air quality and pollutants are known to irritate and impact respiratory health⁶

TAKEOUT: Effective management requires a partnership between the patient, provider and utilization of innovative MedTech



An innovative FDA-approved Medical Device Class II

wheezo® is a handheld battery powered device that records breathing over 30 seconds and analyses the recording for wheeze.

- The breath sounds (and wheeze) are transmitted to the mobile application via Bluetooth
- The wheeze detection algorithm runs in the mobile application
- The engaging mobile application also allows users to log their symptoms, triggers, medication usage and share their in-community data with others
- The mobile application automatically records location specific pollen and air quality information in real-time



Providers and their patients can significantly benefit from recent RPM/RTM CPT reimbursement codes

1 Provider sets patient up on Respi proprietary platform




Provider bills **once**

2 Physiological data is recorded over at least 16 days in given month



Provider bills **monthly**

3 Data sent in real time & clinical staff review RPM data & interact with the patient



Provider bills **monthly**

- Physician's billable amount per patient per year **USD1,350+**
- Respiri Product as a Service (PaaS) per patient billed to physician

CPT 2021 Payment Rates

| CPT Code | Descriptor | Value US\$ (non-facility) |
|----------|--|---------------------------|
| 99453 | Patient set up (once per episode of care) | \$18.77 |
| 99454 | Device delivery/supply (every 30 days, min.16 days of data collection) | \$62.44 |
| 99457 | Patient Monitoring & interactive communication First 20 mins (every 30 days) | \$51.61 |
| 99458 | Patient Monitoring & Communication. Each additional 20 mins (every 30 days) | \$42.22 |
| 99091 | Collection & Review of Physiological Data (every 30 days) | \$59.19 |



Integration Models we Support

- Utilise Respiri's end to end solution

OR

- Integrate into existing 3rd party partner solutions

Technical Integration Approach

- **Discovery:** Define Delivery Requirements; API Integration; Branding; Define Delivery Phases
- **Implementation:** Technical Sign Off; Systems Delivery; Acceptance Testing
- **Support:** During Integration, Deployment and Ongoing

Benefits of Partnering with Respiri

- In House Capability to integrate systems
- MedTech Respiratory Domain Knowledge
- Seamlessly integrate into partner systems



Respiri's integrated solutions can deliver value to all key stakeholders and very well received



Healthcare Professionals

- ✓ A new source of revenue
- ✓ Improved quality of care
- ✓ Better information for evaluation and management

RPM / RTM Providers

- ✓ Partnering with best in class FDA approved medical device
- ✓ Seamless integration into existing health systems
- ✓ New patient cohort, delivering new revenue stream

Patients

- ✓ Improved health and compliance outcomes
- ✓ Reduced hospital admissions
- ✓ Reduced healthcare costs and financial burden



RESPIRI: 2022 and beyond

- International launch will be physician led, rather than pharmacy
- US launch ahead of schedule
- UK soft launch Q1 2022, reimbursement strategy being developed
- Advanced discussions with EU partner and developing reimbursement strategies
- Wearable opening up new therapeutic opportunities that are currently poorly serviced.
- Australia
 - RAMP providing new channel
 - Pharmacy targeting strategy to focus on cost effective engagement with fewer relevant pharmacies



Thank you

RESPIRI

